Table 2.
Related Fascin-1 studies in cancers.
| Cancer type | FSCNs expression | Biological relevance | Model | Year | Author | Reference |
|---|---|---|---|---|---|---|
| Breast cancer | FSCN1 | Diagnosis biomarker | Human Specimens | 2000 | A Grothey | [45] |
| Associated with tumors motility and malignancy | MDA-MB-435 | 2000 | A Grothey | [46] | ||
| Insulin-like growth factor-I receptor-induced Fascin projections | Cell lines (HMEC, BT474, MDA-MB-231, MCF-7) | 2000 | Marina A Guvakova | [47] | ||
| Diagnosis biomarker | Human Specimens | 2005 | Brian J Yoder | [48] | ||
| Diagnosis biomarker | Human Specimens | 2006 | Socorro María Rodríguez-Pinilla | [49] | ||
| Diagnosis biomarker | Human Specimens | 2010 | Y Zhang | [50] | ||
| Regulation of tumor cell proliferation and motility | Cell lines (MDA-MB-435, MDA-MB-231, T-47D) | 2011 | Peng Xing | [51] | ||
| Regulation of tumor cell motility | Human Specimens, Cell lines (MDA-MB-23, T-47D) | 2011 | Monther Al-Alwan | [52] | ||
| Diagnosis biomarker | Human Specimens | 2014 | Ashwini K Esnakula | [53] | ||
| Diagnosis biomarker | Human Specimens | 2014 | Nermeen Salah Youssef | [54] | ||
| Chemoresistant | Cell lines (MDA-MB-231, SK-BR-3, and T-47D) | 2014 | H Ghebeh | [55] | ||
| Regulation of tumor cell motility | Cell lines (MDA-MB-231) | 2014 | Marylynn Snyder | [56] | ||
| Diagnosis biomarker | Human Specimens | 2015 | Kyueng-Whan Min | [57] | ||
| Diagnosis biomarker | Human Specimens | 2015 | Ola M Omran | [58] | ||
| Diagnosis biomarker | Human Specimens | 2016 | Chao-Qun Wang | [59] | ||
| Stemness activity | Cell lines (MDA-MB-231, T-47D) | 2016 | Rayanah Barnawi | [60] | ||
| Regulation of tumor cell motility | Human Specimens, Cell lines (MDA-MB-231, MDA-MB-468, and MCF-7) | 2017 | Chao-Qun Wang | [61] | ||
| Diagnosis biomarker | Human Specimens | 2017 | Hye Jin Lee | [62] | ||
| Regulation of tumor cell metastasis | Cell lines (MDA-MB-231) | 2017 | Lisa S Heinz | [63] | ||
| Diagnosis biomarker | Human Specimens | 2019 | Ata Abbasi | [64] | ||
| Diagnosis biomarker | Human Specimens | 2019 | Ekaterini Christina Tampaki | [65] | ||
| Stemness activiry | Cell lines (MDA-MB-231, T-47D) | 2020 | Rayanah Barnawi | [66] | ||
| Ovarian cancer | FSCN1 | Diagnosis biomarker | Patient-derived cells, Human tissues | 2000 | W Hu | [67] |
| Diagnosis biomarker | Human Specimens | 2008 | Alexandros Daponte | [68] | ||
| Diagnosis biomarker | Human Specimens | 2008 | Chih-kung Lin | [69] | ||
| Diagnosis biomarker | Human Specimens | 2009 | Chih-Kung Lin | [69] | ||
| Diagnosis biomarker | Human Specimens | 2013 | Lars C Hanker | [69] | ||
| Regulation of tumor cell metastasis | Human Specimens, Cell lines (HeyA8, Ovcar5, Tyk-nu, Snu119, and Kuramochi) | 2019 | Sean McGuire | [70] | ||
| Regulation of tumor cell motility | Cell lines (ES-2, SK-OV-3 and NOE) | 2020 | Masato Yoshihara | [71] | ||
| Pancreatic cancer | FSCN1 | Diagnosis biomarker | Human Specimens | 2002 | Anirban Maitra | [72] |
| Diagnosis biomarker | Human Specimens | 2004 | Sharon L Swierczynski | [73] | ||
| Regulation of tumor cell motility | Cell lines (BxPC-3, MIAPaCa-2,AsPC-, PC-1, PC-4 and PC-7) | 2011 | Yan-Feng Xu | [74] | ||
| Diagnosis biomarker | Human Specimens | 2013 | Wen-Chiuan Tsai | [75] | ||
| Regulation of tumor cell metastasis | Human Specimens, PDAC mice model | 2014 | Ang Li | [76] | ||
| Regulation of tumor cell metastasis | Human Specimens, Cell lines (MiaPaCa-2, Aspc-1) | 2014 | Xiao Zhao | [77] | ||
| Diagnosis biomarker | Human Specimens | 2020 | Magdalena Misiura | [78] | ||
| Skin neoplasia | FSCN1 | Diagnosis biomarker | Human Specimens | 2002 | Viktor N Goncharuk | [79] |
| Lung cancer | FSCN1 | Diagnosis biomarker | Human Specimens | 2003 | G Pelosi | [80] |
| Diagnosis biomarker | Human Specimens | 2013 | Yu Teng | [81] | ||
| Diagnosis biomarker | Human Specimens | 2015 | Xiao-Ling Ling | [82] | ||
| Diagnosis biomarker | Human Specimens | 2015 | Aihua Luo | [83] | ||
| Diagnosis biomarker | Human Specimens | 2015 | Wei Zhao | [84] | ||
| Regulation of tumor cell growth and motility | Cell lines (A549, SPC-A-1) | 2016 | Zhigang Liang | [85] | ||
| Diagnosis biomarker | Human Specimens | 2016 | Juanjuan Zhang | [86] | ||
| Diagnosis biomarker | Human Specimens | 2017 | L Yang | [87] | ||
| Regulation of tumor cell motility | Cell lines (A549, H520) | 2018 | Da Zhao | [88] | ||
| Diagnosis biomarker | Human Specimens | 2018 | Yunxia Zhang | [89] | ||
| Regulation of tumor cell metastasis and recurrence | Human Specimens, Cell lines (H1650, H23, H292, LLC) mice animal model |
2019 | Shengchen Lin | [90] | ||
| Diagnosis biomarker | Human Specimens | 2020 | E S Kolegova | [91] | ||
| Regulation of tumor cell metastasis | Human Specimens, Cell lines (H1650, A549, H292, H23, LLC) | 2021 | Shengchen Lin | [92] | ||
| Cholangiocarcinoma | FSCN1 | Diagnosis biomarker | Human Specimens | 2004 | Sharon L Swierczynski | [73] |
| Diagnosis biomarker | Human Specimens | 2007 | Kohji Okada | [93] | ||
| Diagnosis biomarker | Human Specimens | 2009 | Young Hoon Roh | [94] | ||
| Diagnosis biomarker | Human Specimens | 2009 | Kyu Yeoun Won | [95] | ||
| Gastric cancer | FSCN1 | Diagnosis biomarker | Human Specimens | 2004 | Yosuke Hashimoto | [96] |
| Diagnosis biomarker | Human Specimens | 2007 | Wen-Chiuan Tsai | [97] | ||
| Regulation of tumor cell motility | Human Specimens, Cell lines (MKN-28) | 2010 | Seok-Jun Kim | [98] | ||
| Diagnosis biomarker | Human Specimens | 2013 | Hidetaka Yamamoto | [99] | ||
| Diagnosis biomarker | Human Specimens | 2012 | Su Jin Kim | [100] | ||
| Regulation of tumor cell motility | Cell lines (GES-1, MKN45, MKN28, BGC823, AGS and SGC7901) | 2014 | Jun Yao | [101] | ||
| Regulation of tumor cell growth and motility | (HGC-27, MGC-803, MKN-25 and SGC-7901 | 2014 | Lihua Guo | [102] | ||
| Regulation of tumor cell motility | AGS, MNK-45) | 2015 | Yunshan Yang | [103] | ||
| Diagnosis biomarker | In-silico analysis | 2017 | Hua-Chuan Zheng | [104] | ||
| Diagnosis biomarker | Human Specimens | 2018 | Byoung Kwan Son | [105] | ||
| Esophageal Cancer | FSCN1 | Diagnosis biomarker | Human Specimens, Cell lines (EC109, EC18, EC171, EC8712 and SHEEC) | 2006 | H Zhang | [106] |
| Diagnosis biomarker | Human Specimens | 2010 | Li-yan Xue | [107] | ||
| Diagnosis biomarker | Human Specimens | 2017 | Wen-Xia Chen | [108] | ||
| Regulation of tumor cell growth and motility | Cell lines (KYSE150, KYSE180) | 2017 | Fa-Min Zeng | [109] | ||
| Kidney cancer | FSCN1 | Diagnosis biomarker | Human Specimens | 2006 | Richard Zigeuner | [110] |
| Adrenocortical carcinoma | FSCN1 | Diagnosis biomarker | Human Specimens | 2015 | Giada Poli | [111] |
| Regulation of tumor cell growth and motility | Human Specimens, Cell lines (H295R) | 2019 | Giada Poli | [112] | ||
| Colon cancer | FSCN1 | Diagnosis biomarker | Human Specimens | 2006 | Yosuke Hashimoto | [113] |
| Regulation of tumor cell motility | Human Specimens, Cell lines (HT29, SW480, HCT116, CT26) | 2007 | Danijela Vignjevic | [114] | ||
| Regulation of tumor cell motility | Cell lines (SW480, SW1222, and DLD-1), subcutaneous xenograft model | 2007 | Yosuke Hashimoto | [115] | ||
| Diagnosis biomarker | Human Specimens | 2010 | Charles Chan | [116] | ||
| Diagnosis biomarker | Human Specimens | 2012 | Seung Yeop Oh | [117] | ||
| Diagnosis biomarker | Human Specimens | 2011 | Eun-Joo Jung | [118] | ||
| Diagnosis biomarker | Human Specimens | 2013 | Pablo Conesa-Zamora | [119] | ||
| Regulation of tumor growth and metastasis | Cell lines (SW480, HT29, LS174T, SW620, and LoVo) | 2014 | Y Feng | [120] | ||
| Regulation of tumor cell growth and motility | Transgenic mice | 2014 | Marie Schoumacher | [121] | ||
| Diagnosis biomarker | Human Specimens | 2015 | Josephine C Adams | [122] | ||
| Diagnosis biomarker | Human Specimens | 2018 | Barbara M Piskor | [123] | ||
| Diagnosis biomarker | Human Specimens | 2020 | Chao-Qun Wang | [124] | ||
| Diagnosis biomarker | In-silico analysis | 2020 | Shuai Shi | [125] | ||
| Diagnosis biomarker | Human Specimens | 2021 | Athanasios Tampakis | [126] | ||
| Prostate cancer | FSCN1 | Regulation of tumor cell motility | Human Specimens, Cell lines (DU145), Orthotopic prostate xenograft models |
2009 | Andrew D Darnel | [127] |
| Diagnosis biomarker | Human Specimens | 2014 | Daniel C Dim | [128] | ||
| Diagnosis biomarker | Human Specimens | 2017 | Matthew T Jefferies | [129] | ||
| Oral cancer | FSCN1 | Regulation of tumor cell motility | Cell lines (OECM-1, SCC-25) | 2009 | Su-Feng Chen | [130] |
| proteases activity and tumor cell motility | Cell lines (YD-10B, HSC-2, HSC-3, Ca9.22 OSCC) | 2018 | Min Kyeong Lee | [131] | ||
| Melanoma | FSCN1 | Regulation of tumor cell motility | Cell lines (A375MM, CHL-1, WM266.4, MV3) | 2010 | Ang Li | [132] |
| Regulation of tumor cell growth and motility | Fascin1 -/- mice | 2013 | Yafeng Ma | [133] | ||
| Regulation of tumor angiogenesis | Cell lines (B16F0) | 2013 | Yafeng Ma | [134] | ||
| Stemness activity | Cell lines (WM793, WM39) | 2018 | Jiaxin Kang | [135] | ||
| Regulation of tumor cell growth | Cell lines (WM793), subcutaneous xenograft model | 2021 | Byung-Soo Kang | [136] | ||
| FSCN family | Diagnosis biomarker | In-silico analysis | 2021 | Cong Deng | [44] | |
| Bladder cancer | FSCN1 | Regulation of tumor cell viability and motility | Human Specimens, Cell lines (BOY, T24m KK47) | 2010 | T Chiyomaru | [137] |
| Diagnosis biomarker | Human Specimens | 2013 | Mohamed Abd El-Rehim | [138] | ||
| Lymphoma | FSCN1 | Diagnosis biomarker | Human Peripheral blood mononuclear cells | 2011 | Andrea K Kress | [139] |
| Regulation of tumor cell motility | Cell lines (LCL-B, LCL-721, LCLs LCL-3 and LCL-4) | 2014 | Caroline F Mohr | [140] | ||
| Leukemia | FSCN1 | Diagnosis biomarker | Human Specimens | 2018 | Nabila El Kramani | [141] |
| Liver cancer | FSCN1 | Regulation of tumor cell viability and motility | Human Specimens, Cell lines (HLE, Hep3B, Huh7) | 2011 | Yoshihiro Hayashi | [142] |
| Diagnosis biomarker | Human Specimens | 2011 | Chih-Kung Lin | [143] | ||
| Diagnosis biomarker | Human Specimens | 2012 | Xiaodan Huang | [144] | ||
| Chemoresistant | Cell lines (SNU387, Huh7, Hep3B, and SNU449) | 2018 | Yuanbiao Zhang | [145] | ||
| Endometrioid carcinoma | FSCN1 | Diagnosis biomarker | Human Specimens | 2012 | Banu Dogan Gun | [146] |
| Head and neck cancers | FSCN1 | Diagnosis biomarker | Human Specimens | 2014 | Konstantinos Papaspyrou | [147] |
| Diagnosis biomarker | Human Specimens, Cell lines (OECM1, SAS, CGC8, and CGC9) | 2015 | Li-Yu Lee | [148] | ||
| Brain cancer | FSCN1 | Regulation of tumor cell motility | Cell lines (U251) | 2015 | Neil T Hoa | [149] |
| Cervical cancer | FSCN1 | Regulation of tumor growth | CaSki, subcutaneous xenograft model | 2018 | Xian Li | [150] |
| Diagnosis biomarker | Human Specimens | 2018 | Zohreh Yousefi Ghalejoogh | [151] | ||
| Cardia cancer | FSCN1 | Diagnosis biomarker | Human Specimens | 2019 | Li Wei | [152] |
As a well-known molecule, Fascin-1 can be used as a diagnostic marker and is essential for cell growth and motility in multiple cancer types. The table lists the Fascin-1-related studies from 2000 to 2021, including the biological relevance of cancer types, validated with human tissues or tumor cell lines, and established in which tumor cell model.